UK markets open in 52 minutes

Virpax Pharmaceuticals, Inc. (VRPX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.9700+0.1000 (+3.48%)
At close: 04:00PM EST
2.9000 -0.07 (-2.36%)
After hours: 07:43PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 47.45M
Enterprise value 38.05M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.14
Enterprise value/revenue N/A
Enterprise value/EBITDA -4.46

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-56.05%
S&P500 52-week change 321.05%
52-week high 336.0000
52-week low 32.7900
50-day moving average 33.7944
200-day moving average 35.4830

Share statistics

Avg vol (3-month) 3969.55k
Avg vol (10-day) 3255.38k
Shares outstanding 511.71M
Implied shares outstanding 6N/A
Float 86.16M
% held by insiders 125.01%
% held by institutions 127.75%
Shares short (30 Dec 2021) 4202.98k
Short ratio (30 Dec 2021) 40.1
Short % of float (30 Dec 2021) 42.31%
Short % of shares outstanding (30 Dec 2021) 41.73%
Shares short (prior month 29 Nov 2021) 490.95k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-24.56%
Return on equity (ttm)-45.96%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
Net income avi to common (ttm)-8.64M
Diluted EPS (ttm)-1.9110
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)41.71M
Total cash per share (mrq)3.56
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)23.88
Book value per share (mrq)3.54

Cash flow statement

Operating cash flow (ttm)-9.77M
Levered free cash flow (ttm)-6.83M